1. 171P Pharmacodynamic (PD) biomarker analysis from CheckMate (CM) 8KX: A multitumor study of a subcutaneous (SC) formulation of nivolumab (NIVO) monotherapy. (December 2022) Authors: Jackson, C.G.C.A.; Perumal, D.; Lugowska, I.; O'Donnell, A.; North, R.T.; Calvo Ferrandiz, P.A.; Latten-Jansen, L.M.; Sánchez, C.G.; Medina Rodríguez, L.M.; Santoro, A.; Li, L.; Sidik, K.; Tang, T.; Deutsch, J.S.; Taube, J.; Horak, C.; Ravimohan, S.; Lonardi, S. Journal: Immuno-oncology technology Issue: Volume 16(2022)Supplement 1 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. 2006 A phase III multicenter trial comparing two different sequences of second/third line therapy (cetuximab/irinotecan followed by FOLFOX versus FOLFOX followed by cetuximab/irinotecan) in metastatic K-RAS wt colorectal cancer (mCC) patients, refractory to FOLFIRI/Bevacizumab). Issue 3 (September 2015) Authors: Cascinu, S.; Lonardi, S.; Rosati, G.; Nasti, G.; Zaniboni, A.; Romiti, A.; Aglietta, M.; Bilancia, D.; Iaffaioli, V.; Zagonel, V.; Giordano, M.; Corsi, D.; Ferraù, F.; Labianca, R.; Berardi, R.; Rulli, E.; Floriani, I. Journal: European journal of cancer Issue: Volume 51:Issue 3(2015:Feb.) Page Start: S329 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. 2108 Subgroup analysis by KRAS status in RAISE: A randomized, double-blind phase III study of irinotecan, folinic acid, and 5-fluorouracil (FOLFIRI) plus ramucirumab or placebo in patients with metastatic colorectal carcinoma progression during or following first-line combination therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine. (September 2015) Authors: Van Cutsem, E.; Obermannova, R.; Bodoky, G.; Prausová, J.; García-Carbonero, R.; Ciuleanu, T.; Alfonso, P Garcia; Portnoy, D.; Cohn, A.; Yamazaki, K.; Clingan, P; Yoshino, T.; Polikoff, J.; Lonardi, S.; Macarulla, T.; Yang, L.; Nasroulah, F. Journal: European journal of cancer Issue: Volume 51:(2015)Supplement 3 Page Start: S365 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. 2123 Exposure-response (E-R) relationship of Ramucirumab (RAM) from a global, randomized, double-blind, Phase 3 study of patients (Pts) with advanced 2nd line colorectal cancer. (September 2015) Authors: Cohn, A. Lee; Yoshino, T.; Obermannova, R.; Bodoky, G.; Prausova, J.; Garcia-Carbonero, R.; Ciuleanu, T. Eliade; Garcia-Alfonso, P.; Portnoy, D.C.; Van Cutsem, E.; Yamazaki, K.; Clingan, P.R.; Polikoff, J.; Lonardi, S.; Gao, L.; Yang, L.; Chang, S.C.; Ferry, D.; Nasroulah, F.; Tabernero, J. Journal: European journal of cancer Issue: Volume 51:(2015)Supplement 3 Page Start: S372 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. 2178 Locoregional treatment for advanced biliary tract cancer (aBTC): Evaluation of efficacy and safety. (September 2015) Authors: Marsico, V.A.; Vasile, E.; Vivaldi, C.; Vaccaro, V.; Brandi, G.; Leone, F.; Milella, M.; Fornaro, L.; Aprile, G.; Rumano, L.V.; Santini, D.; Carcea, E.; Aliberti, C.; Lonardi, S. Journal: European journal of cancer Issue: Volume 51:(2015)Supplement 3 Page Start: S393 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. 65P Atezolizumab plus bevacizumab versus lenvatinib for unresectable hepatocellular carcinoma: A large real life worldwide population. (December 2022) Authors: Rimini, M.; Casadei Gardini, A.; Persano, M.; Suda, G.; Tada, T.; Shimose, S.; Kudo, M.; Cheon, J.; Finkelmeier, F.; Rimassa, L.; Presa, J.; Masi, G.; Yoo, C.; Lonardi, S.; Tovoli, F.; Piscaglia, F.; Iavarone, M.A.; Scartozzi, M.; Burgio, V.; Cascinu, S. Journal: Immuno-oncology technology Issue: Volume 16(2022)Supplement 1 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. 67P Real-world data for atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. (December 2022) Authors: Persano, M.; Rimini, M.; Tada, T.; Suda, G.; Shimose, S.; Kudo, M.; Cheon, J.; Finkelmeier, F.; Rimassa, L.; Presa, J.; Masi, G.; Yoo, C.; Lonardi, S.; Piscaglia, F.; Burgio, V.; Scartozzi, M.; Cascinu, S.; Casadei Gardini, A. Journal: Immuno-oncology technology Issue: Volume 16(2022)Supplement 1 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. Advanced age and liability to oxaliplatin‐induced peripheral neuropathy: post hoc analysis of a prospective study. Issue 5 (17th December 2012) Authors: Argyriou, A. A.; Briani, C.; Cavaletti, G.; Bruna, J.; Alberti, P.; Velasco, R.; Lonardi, S.; Cortinovis, D.; Cazzaniga, M.; Campagnolo, M.; Santos, C.; Kalofonos, H. P. Journal: European journal of neurology Issue: Volume 20:Issue 5(2013:May) Page Start: 788 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. Association of the HLA‐G 3′UTR polymorphisms with colorectal cancer in Italy: a first insight. (21st December 2015) Authors: Garziera, M.; Catamo, E.; Crovella, S.; Montico, M.; Cecchin, E.; Lonardi, S.; Mini, E.; Nobili, S.; Romanato, L.; Toffoli, G. Journal: International journal of immunogenetics Issue: Volume 43:Number 1(2016:Feb.) Page Start: 32 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. Capecitabine in advanced hepatocellular carcinoma: a multicenter experience. (February 2019) Authors: Pelizzaro, F.; Sammarco, A.; Pastorelli, D.; Giovanis, P.; Dadduzio, V.; Rizzato, M.D.; Lombardi, G.; Lonardi, S.; Peserico, G.; Imondi, A.; Sartori, A.; Maddalo, G.; Farinati, F. Journal: Digestive and liver disease Issue: Volume 51(2019)Supplement 1 Page Start: e40 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗